New Delhi: An expert panel constituted by the government has recommended against granting permission to Serum Institute of India (SII) to conduct phase two and three clinical trials of Covavax vaccine on children aged between 2-17 years, said sources on Thursday.
According to the sources, the government panel has asked the institute to complete trials on adults first.
The CEO of Pune-based SII, Adar Poonawalla, had in March this year said that the trials for 'Covavax', the Covid-19 vaccine developed by US-based vaccine manufacturer Novavax, have begun in India, and added that he is hoping the vaccine launch will take place by September this year.
The Serum Institute of India had applied to the Drugs Controller General of India (DCGI) on Monday seeking permission to conduct clinical trials of Covavax on children at 10 sites.
